briakinumab   

GtoPdb Ligand ID: 9213

Synonyms: ABT-874 | J-695 | J695 | Ozespa
Compound class: Antibody
Comment: Briakinumab is a recombinant, fully human, IgG1 investigational monoclonal antibody targeting the shared p40 subunit of IL-12 and IL-23. Peptide sequences matching those of briakinumab are claimed in patent US6914128 'Human antibodies that bind human IL-12 and methods for producing' [2].
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: pericyazine

No information available.
Summary of Clinical Use
Results from a Phase 2 clinical trial (NCT00292396) evaluating briakinumab in patients with moderate to severe chronic plaque psoriasis are reported in [1]. Several Phase 3 trials comparing briakinumab against placebo, etanercept and methotrexate (two approved anti-psoriatic drugs) for moderate to severe chronic plaque psoriasis (link here to a list of these trials on ClinicalTrials.gov) have been completed. Clinical development of briakinumab for rheumatoid arthritis, Crohn's disease and multiple sclerosis has been terminated. As of May 2017, there are no active clinical trials evaluating this antibody.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT00292396 Efficacy and Safety of ABT-874 in Subjects With Moderate to Severe Chronic Plaque Psoriasis Phase 2 Interventional AbbVie